Skip to main content

Therapeutic Goods (Poisons Standard) (COVID-19 Treatment - Gilead) (Remdesivir) Labelling Exemption 2021

This labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.

Published
Last updated

Related content

Help us improve this page

This form is anonymous. If you would like a response from us, please visit Contact us.